IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Inclusion Criteria:

• Participants must be HLA-A*02:01-positive

• Participants must have histologically confirmed Stage IV or unresectable Stage IIImelanoma

• Archived or fresh tumor tissue sample that must be confirmed as adequate

• Participants must have measurable disease per RECIST 1.1

• Participant must have BRAF V600 mutation status determined

• Participants must have an Eastern Cooperative Oncology Group (ECOG) performancestatus score of 0 or 1

• Male and female participants of childbearing potential who are sexually active witha non-sterilized partner must agree to use highly effective methods of birth controlfrom the study screening date until 5 months after the final dose of studyintervention

Exclusion Criteria:

• Participants with a history of a malignant disease other than those being treated inthis study

• Participants with untreated, active, or symptomatic central nervous system (CNS)metastases or carcinomatous meningitis

• Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients

• Participants with clinically significant pulmonary disease or impaired lung function

• Participants with clinically significant cardiac disease or impaired cardiacfunction

• Participants with active autoimmune disease requiring immunosuppressive treatment

• Participants with any medical condition that is poorly controlled or that would, inthe Investigator's or Sponsor's judgment, adversely impact the participant'sparticipation in the clinical study due to safety concerns, compliance with clinicalstudy procedures, or interpretation of study results

• Participants who received prior systemic anticancer therapy for unresectable ormetastatic melanoma

• Participants with a history of a life-threatening AE related to prior anti-PD-(L)1or anti-LAG-3